PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8739285-8	1996	In contrast, with enalapril treatment PAH clearance after ACTZ tended to rise (29 +/- 12 ml/ min/1.73 m2, p = 0.07).	Enalapril	18-27	CD59 molecule (CD59 blood group)	Homo sapiens	93-98	
8678058-3	1996	We report a double-blind study of the effect of 5 mg enalapril once daily compared with placebo in patients with nondiabetic severe chronic renal impairment (plasma creatinine 2.8 to 6.8 mg/dL; mean creatinine clearance 15 mL/min/1.73 m2) followed for up to 2 years.	Enalapril	53-62	CD59 molecule (CD59 blood group)	Homo sapiens	226-231	
9036753-7	1997	Glomerular filtration rate changed from 79 +/- 20 to 78 +/- 19 ml/min/1.73 m2 with placebo, and from 85 +/- 21 to 73 +/- 27 ml/min/1.73 m2 with enalapril (p = 0.051).	Enalapril	144-153	CD59 molecule (CD59 blood group)	Homo sapiens	127-132	
7830033-7	1995	Enalapril reduced albumin excretion from 1090 +/- 281 micrograms min-1 to 742 +/- 246 micrograms min-1 (P < 0.01) and total protein excretion from 2.0 +/- 0.4 g per 24 h to 1.3 +/- 0.4 per 24 h whereas doxazosin was without effect.	Enalapril	0-9	CD59 molecule (CD59 blood group)	Homo sapiens	65-70	
7742150-6	1995	After oral enalapril 10 mg the absolute fall in serum ACE activity was significantly larger in DD than II subjects at 2, 4, and 6 h (by 9.0 (95% CI 0.7-17.2), 10.7 (3.8-17.6), and 9.7 (2.8-16.6) nmol ml-1 min-1 respectively), but not at 24 h (fall in II > DD by 1.1 (-8.9 to 6.7) nmol ml-1 min-1).	Enalapril	11-20	CD59 molecule (CD59 blood group)	Homo sapiens	205-210	
7742150-6	1995	After oral enalapril 10 mg the absolute fall in serum ACE activity was significantly larger in DD than II subjects at 2, 4, and 6 h (by 9.0 (95% CI 0.7-17.2), 10.7 (3.8-17.6), and 9.7 (2.8-16.6) nmol ml-1 min-1 respectively), but not at 24 h (fall in II > DD by 1.1 (-8.9 to 6.7) nmol ml-1 min-1).	Enalapril	11-20	CD59 molecule (CD59 blood group)	Homo sapiens	293-298	
7830033-7	1995	Enalapril reduced albumin excretion from 1090 +/- 281 micrograms min-1 to 742 +/- 246 micrograms min-1 (P < 0.01) and total protein excretion from 2.0 +/- 0.4 g per 24 h to 1.3 +/- 0.4 per 24 h whereas doxazosin was without effect.	Enalapril	0-9	CD59 molecule (CD59 blood group)	Homo sapiens	97-102	
8158883-4	1994	The mean fall in glomerular filtration rate in 18 enalapril-treated patients is 8.4 +/- 9.4 ml/min/1.73 m2 after four years; 7.5 +/- 9.8 ml/min/1.73 m2, occurred during the first six months treatment.	Enalapril	50-59	CD59 molecule (CD59 blood group)	Homo sapiens	95-100	
8158883-4	1994	The mean fall in glomerular filtration rate in 18 enalapril-treated patients is 8.4 +/- 9.4 ml/min/1.73 m2 after four years; 7.5 +/- 9.8 ml/min/1.73 m2, occurred during the first six months treatment.	Enalapril	50-59	CD59 molecule (CD59 blood group)	Homo sapiens	140-145	
2832173-5	1988	Treatment with enalapril, in the absence of frusemide, was associated with a fall in mean blood pressure from 89 +/- 5 mmHg to 85 +/- 4 mmHg (P less than 0.02) and a rise in renal blood flow from 424 +/- 202 ml min-1 to 494 +/- 225 ml min-1 (P less than 0.02), but cardiac output and glomerular filtration rate were again unchanged.	Enalapril	15-24	CD59 molecule (CD59 blood group)	Homo sapiens	211-216	
2544817-5	1989	On the enalapril intake day, creatinine clearance increased from 113.7 +/- 5.6 before the meal to 128.3 +/- 5.8 ml/min/1.73 m2 after the meal (p less than 0.01).	Enalapril	7-16	CD59 molecule (CD59 blood group)	Homo sapiens	115-120	
8346593-5	1993	In the enalapril group, the median decline in GFR was -0.20 (range, +0.18 to -7.11) mL/min/1.73 m2/month, and in the control group, it was -0.31 (+0.01 to -1.97) mL/min/1.73 m2/month (p < 0.05).	Enalapril	7-16	CD59 molecule (CD59 blood group)	Homo sapiens	87-92	
8346593-5	1993	In the enalapril group, the median decline in GFR was -0.20 (range, +0.18 to -7.11) mL/min/1.73 m2/month, and in the control group, it was -0.31 (+0.01 to -1.97) mL/min/1.73 m2/month (p < 0.05).	Enalapril	7-16	CD59 molecule (CD59 blood group)	Homo sapiens	165-170	
1752291-7	1991	Insulin sensitivity increased significantly during treatment with enalapril (with enalapril: Ins I: 11.3 +/- 3.0, Ins II: 20.0 +/- 3.4 and Ins III: 20.6 +/- 3.9 mg kg-1 min-1 glucose (mean +/- SD); without enalapril: Ins I: 8.7 +/- 2.3, Ins II: 13.7 +/- 3.0 and Ins III: 15.5 +/- 3.1 mg kg-1 min-1 glucose; P less than 0.05).	Enalapril	66-75	CD59 molecule (CD59 blood group)	Homo sapiens	169-174	
1752291-7	1991	Insulin sensitivity increased significantly during treatment with enalapril (with enalapril: Ins I: 11.3 +/- 3.0, Ins II: 20.0 +/- 3.4 and Ins III: 20.6 +/- 3.9 mg kg-1 min-1 glucose (mean +/- SD); without enalapril: Ins I: 8.7 +/- 2.3, Ins II: 13.7 +/- 3.0 and Ins III: 15.5 +/- 3.1 mg kg-1 min-1 glucose; P less than 0.05).	Enalapril	66-75	CD59 molecule (CD59 blood group)	Homo sapiens	292-297	
2832173-5	1988	Treatment with enalapril, in the absence of frusemide, was associated with a fall in mean blood pressure from 89 +/- 5 mmHg to 85 +/- 4 mmHg (P less than 0.02) and a rise in renal blood flow from 424 +/- 202 ml min-1 to 494 +/- 225 ml min-1 (P less than 0.02), but cardiac output and glomerular filtration rate were again unchanged.	Enalapril	15-24	CD59 molecule (CD59 blood group)	Homo sapiens	235-240	
3004546-4	1986	In patients with severe renal impairment (GFR values below 30 ml min-1 1.73 m-2) significantly smaller doses of enalapril maleate will be required than in patients with normal or less severely impaired renal function.	Enalapril	112-129	CD59 molecule (CD59 blood group)	Homo sapiens	65-70